Overall Fundamental outlook

* ALKEM makes the list of companies with the best fundamentals at present.

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

Revenues for ALKEM are forecasted to decline from last year's levels, prompting caution among investors. When revenues fall, it can have a significant negative impact on the company's bottom line, reducing profitability and making the stock less attractive to risk-averse investors.

Financial Ratios:

currentRatio 2.486000
forwardPE 28.829575
debtToEquity 17.056000
earningsGrowth 0.111000
revenueGrowth 0.172000
grossMargins 0.624410
operatingMargins 0.206740
trailingEps 197.510000
forwardEps 213.950000

ALKEM's current ratio of 2.486 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring ALKEM is unlikely to face difficulties in meeting immediate financial obligations.
ALKEM's Forward PE is in an attractive range, meaning its stock price aligns well with earnings and isn't inflated. This creates room for growth, making it a solid investment opportunity for those looking to benefit from potential price appreciation.
ALKEM's low Debt-to-Equity ratio indicates the company is not over-leveraged. By limiting its dependence on debt, ALKEM reduces its financial risk and demonstrates a strong capital structure, making it a more stable investment option for those wary of excessive borrowing.
With positive earnings and revenue growth, Alkem Laboratories Limited is on a path to expand its business. This strong financial performance suggests the company will continue to grow, as increasing profits and revenue highlight a healthy outlook.
ALKEM's positive gross and operating margins reflect its ability to generate profits from operations. These margins demonstrate efficient cost control and profitability, indicating strong financial health for the company.
Alkem Laboratories Limited's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

ALKEM's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about ALKEM's ability to grow.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


Analysts' buy bias for ALKEM signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to ALKEM, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.